IRIDEX CORP
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
About Iridex
Electromedical & Electrotherapeutic Apparatus, SIC 3845
IRIDEX Corporation is an ophthalmic medical technology company that develops and commercializes products and procedures for treating sight-threatening eye conditions, primarily glaucoma and retinal diseases. Its core offerings include laser consoles, consumable probes, and delivery devices powered by proprietary MicroPulse and Endpoint Management technologies, alongside continuous-wave laser modes. Key console lines include the Cyclo G6 for glaucoma, portable IQ systems and the PASCAL platform for medical retina, and OcuLight systems for surgical retina. The company also sells single-use consumable probes, such as MicroPulse P3, G-Probe, and EndoProbe handpieces, while providing repair and maintenance services. Customers are primarily ophthalmologists who use these products in hospital operating rooms, ambulatory surgical centers, offices, and clinics.
The company markets its products in the United States and Germany predominantly through a direct sales force. Internationally, sales are conducted primarily through Topcon Corporation and independent distributors across markets including Italy, the United Kingdom, and India. The company maintains its corporate headquarters and executive offices in Mountain View, California.
Summary of the business section of Iridex's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IRIDEX CORP
- Founded
- 1989
- Headquarters
- Mountain View, CA
- Address
- 1212 Terra Bella Ave 94043
- Phone
- (650) 940-4700
- Website
- iridex.com
- Employees
- 93, Jan 3, 2026
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- January 3
- Auditor
- BPM LLP, San Jose, California
Stock & identifiers
- Ticker
- IRIX
- Exchange
- Nasdaq
- Shares outstanding
- 18M, Aug 13, 2026
- Public float
- $14.24M, Jun 27, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1006045
- CUSIP
- 462684101
- ISIN
- US4626841013
- EIN
- 77-0210467
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Patrick Mercer | President and CEO, Director | 468,784 |
| Romeo R. Dizon | Chief Financial Officer | 185,306 |
| William M. Moore | Director | 402,000 |
| Yu-Hao Chen | Director | – |
| Scott Shuda | Director | 144,523 |
| Beverly A. Huss | Director | 92,639 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 PEO1 | $901.90K | $785.64K | $403.42K | $58 | – |
| FY2024 PEO1 | $564.94K | $530.46K | $699.06K | $83 | – |
| FY2024 PEO2 | $795.84K | $1.97M | $699.06K | $83 | – |
| FY2023 PEO1 | $397.20K | $406.20K | $437.45K | $140 | – |
| FY2022 PEO1 | $765.77K | -$915.93K | $496.46K | $33 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of January 3, 2026, we had a total of 93 full-time equivalent employees engaged in our ongoing operations, including 42 in operations (including manufacturing, quality, logistics and service), 26 in sales and marketing, 11 in research and development and 14 in finance and administration.”
Corporate history
Events identified from SEC filings